Characterization of CHEK2 mutations in prostate cancer
Related Experiment Video
Updated: Aug 7, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Xianglin Wu1, Xiangyang Dong, Wanguo Liu
1Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Abstract:
The checkpoint kinase 2 (CHEK2, also known as CHK2) is a tumor suppressor that participates in the DNA damage-signaling pathway. It is phosphorylated and activated following DNA damage, resulting in cell cycle arrest and apoptosis. Previously, we reported germline CHEK2 mutations in patients with prostate cancer. In this study, we have identified two novel somatic CHEK2 mutations, c.349A > G (p.R117G) and c.967A > C (p.E321K), in prostate tumor specimens and investigated the functions of these mutants in vivo. We have shown that most of the germline CHEK2 mutations and one somatic mutation (p.R117G) within FHA domain have modestly reduced CHEK2 kinase activity in comparison with wild-type CHEK2 while the other somatic mutation (p.E321K) within the kinase domain of CHEK2 totally abolished CHEK2 kinase activity. Given that several clinical CHEK2 mutations reside in the Forkhead-associated (FHA) domain, we further generated a series of missense mutations within this domain and demonstrated the requirement of an intact FHA domain for the full activation of CHEK2. Taken together, these results provide evidence that both germline and somatic CHEK2 mutations identified in prostate cancer may contribute to the development of prostate cancer through the reduction of CHEK2 activation in response to DNA damage and/or oncogenic stress.
Insights
Checkpoint kinase 2 (CHEK2) mutations, both inherited and acquired, can impair its DNA damage response, potentially contributing to prostate cancer development by reducing CHEK2 activation.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- Checkpoint kinase 2 (CHEK2) is a crucial tumor suppressor involved in DNA damage response pathways.
- CHEK2 activation via phosphorylation leads to cell cycle arrest and apoptosis.
- Germline CHEK2 mutations have been previously linked to prostate cancer susceptibility.
Purpose of the Study:
- To identify and functionally characterize novel somatic CHEK2 mutations in prostate tumors.
- To investigate the impact of identified germline and somatic CHEK2 mutations on kinase activity.
- To elucidate the role of the Forkhead-associated (FHA) domain in CHEK2 activation and function.
Main Methods:
- Identification of somatic CHEK2 mutations (c.349A > G [p.R117G] and c.967A > C [p.E321K]) in prostate tumor specimens.
- In vivo functional investigation of identified CHEK2 mutants.
- Assessment of kinase activity for wild-type, germline, and somatic CHEK2 variants.
- Generation and analysis of missense mutations within the CHEK2 FHA domain.
Main Results:
- Two novel somatic CHEK2 mutations, p.R117G and p.E321K, were identified in prostate tumors.
- Most germline and the somatic p.R117G mutation showed reduced CHEK2 kinase activity.
- The somatic p.E321K mutation completely abolished CHEK2 kinase activity.
- An intact FHA domain is essential for the full activation of CHEK2.
Conclusions:
- Both germline and somatic CHEK2 mutations found in prostate cancer can reduce CHEK2 activation.
- Impaired CHEK2 activation in response to DNA damage or oncogenic stress may contribute to prostate cancer development.
- These findings highlight the importance of CHEK2 in prostate tumorigenesis and DNA repair.
Related Concept Videos
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Abnormal Proliferation
